Sign In/ Sign Up
Pioglitazone reduces major adverse CV events in prediabetes, diabetes
Jan 15, 2017
In people with insulin resistance, prediabetes or diabetes, pioglitazone is associated with a decreased risk for major adverse cardiovascular events, study data show.
However, pioglitazone may increase risks for heart failure, bone fracture, edema and weight gain, according to the researchers...